European Biotech Acquisition Corp. Units
EBACU
EBACU was delisted on the 2nd of March, 2023.
18 hedge funds and large institutions have $8.97M invested in European Biotech Acquisition Corp. Units in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.
10% less funds holding
Funds holding: 20 → 18 (-2)
30% less capital invested
Capital invested by funds: $12.8M → $8.97M (-$3.78M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$486K |
| 2 |
Jane Street
New York
|
+$25.2K |
| 3 |
CCM
Condor Capital Management
Martinsville,
New Jersey
|
+$12.9K |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$3.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
-$2.15M |
| 2 |
SMA
Sage Mountain Advisors
Atlanta,
Georgia
|
-$985K |
| 3 |
Calamos Advisors
Naperville,
Illinois
|
-$981K |
| 4 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$147K |
| 5 |
WC
Wealthspring Capital
West Harrison,
New York
|
-$91.6K |
EBACU Hedge Fund Activity: Q3 2022 in Review
18 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Units (EBACU) for Q3 2022, worth a combined $8.97M — down 30% from $12.8M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of EBACU and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Cubist Systematic Strategies, opening a new position worth an estimated $486K. The largest seller was First Trust Capital Management, exiting entirely with an estimated $2.15M sold.
- 18 institutional investors held European Biotech Acquisition Corp. Units (EBACU) as of Q3 2022, down from 20 in Q2 2022.
- Funds reported $8.97M of European Biotech Acquisition Corp. Units stock for Q3 2022, down 30% quarter-over-quarter.
- 2 funds opened new European Biotech Acquisition Corp. Units positions in Q3 2022 and 4 closed out, a net change of -2 holders.
- The largest European Biotech Acquisition Corp. Units buyer in Q3 2022 was Cubist Systematic Strategies, an estimated $486K added.
- The largest European Biotech Acquisition Corp. Units seller in Q3 2022 was First Trust Capital Management, an estimated $2.15M sold.
Based on aggregated 13F filings for Q3 2022.